Multiple Sclerosis Journal

Papers
(The H4-Index of Multiple Sclerosis Journal is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Mitochondrial measures in neuronally enriched extracellular vesicles predict brain and retinal atrophy in multiple sclerosis192
Depression is a core symptom of multiple sclerosis: No79
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – Yes59
Pseudocystic inflammatory demyelinating lesions in multiple sclerosis: A clinical, radiological, and pathological description57
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary53
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088. DOI: 10.1177/13524585241260564.53
ACTRIMS Forum 2021 – Invited Program51
Inclusion of optic neuritis in dissemination in space improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis50
The future for non-pharmacological treatments in MS: Looking back and moving forward48
Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein–associated disease48
Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibility loci47
Thematic analysis of multiple sclerosis research by enhanced strategic diagram44
Well-being at midlife: Correlates of mental health in ambulatory menopausal women with multiple sclerosis42
Reliability of paramagnetic rim lesion detection at 1.5T MRI in multiple sclerosis patients42
Time to move past typical syndromes in the diagnosis of multiple sclerosis41
Two years of COVID-19 in the MS community: What have we learnt so far?41
The Finger Dexterity Test: Validation study of a smartphone-based manual dexterity assessment39
Therapy challenges for NMOSD in a patient with HIV39
The role of body fat in multiple sclerosis susceptibility and severity: A Mendelian randomisation study39
Sars-CoV2 infection in pregnant women with multiple sclerosis38
Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis38
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial37
A closer look at reported colitis in association with multiple sclerosis treatments36
Severe febrile neutropenia associated with satralizumab in an Argentinian NMOSD patient—Commentary35
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS34
Risk of depression and anxiety in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea33
Longitudinal evaluation of serum MOG-IgG titers in MOGAD after initiation of maintenance immunoglobulin: A case series32
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE)31
Depression readmission risk is elevated in multiple sclerosis compared to other chronic illnesses31
From discovery to replication: Power and definitions matter for multiple sclerosis severity31
Artificial intelligence will change MS care within the next 10 years: No31
0.22872805595398